Insulet (NASDAQ: PODD) reported Q2 EPS of $0.55, $0.01 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $488.5 million versus the consensus estimate of $460.4 million.

2024 Outlook:

Revenue Guidance (in constant currency):

For the year ending December 31, 2024, the Company is raising its expected revenue growth to a range of 16% to 19% (previously 14% to 18%). Revenue growth ranges by product line are:

Total Omnipod of 18% to 21% (previously 15% to 19%)

U.S. Omnipod of 18% to 21% (previously 17% to 21%)
International Omnipod of 18% to 21% (previously 12% to 15%)

Drug Delivery of (50)% to (40)% (previously (60)% to (50)%)

For the quarter ending September 30, 2024, the Company expects revenue growth of 18% to 21%. Revenue growth ranges by product line are:

Total Omnipod of 21% to 24%

U.S. Omnipod of 21% to 24%
International Omnipod of 21% to 24%

Drug Delivery of (70)% to (65)% (approximately $3 million to $4 million)

For earnings history and earnings-related data on Insulet (PODD) click here.